HyQvia® treatment is a 10% subcutaneous immunoglobulin treatment facilitated by recombinant human hyaluronidase. Learn more about HyQvia®'s mode of action and why this improves bioavailability. This innovative therapy utilizes a dosage interval every 2-4 weeks.1,2
Video
Helpful guide for subcutaneous immunoglobulins therapy start with our products Cuvitru® and HyQvia®. In this clickable brochure, you will find dosing and switch examples, main characteristics of the products and descriptions of patients that might benefit from a subcutaneous therapy.
Highlights of the biennial European Society for Immunodeficiencies conference (ESID 2022) under the title “Dysregulation and hyperinflammation in inborn errors of immunity” from 12th to 15th October 2022.
In this brochure you will find valuable information about all our immunoglobulin products, summarized with facts, figures and graphics.
An overview of our materials to support your patients with immunodeficiencies.
Our infusion and infection diary helps your patients to keep track of their treatment and state of health.
